Benitec生物药店筹集了1亿美元的库存资金,用于推进稀有疾病的基因疗法。 Benitec Biopharma raised $100 million in a stock offering to advance gene therapies for rare diseases.

Benitec Biopharma公司以每股13.50美元的价格向Suvretta资本公司公开出售593万股和148万股。 承保人可以选择购买更多的股票。 Benitec Biopharma Inc. has priced a $100 million common stock offering, selling 5.93 million shares publicly and 1.48 million shares to Suvretta Capital at $13.50 each, with underwriters holding an option to buy more shares. 预计这项提议将于2025年11月7日结束,目的是资助利用ddRNAi平台为Oculopharyngeal肌肉萎缩症等疾病开发基因疗法。 The offering, expected to close on November 7, 2025, aims to fund development of gene therapies for conditions like Oculopharyngeal Muscular Dystrophy using its ddRNAi platform. 收益还将支持周转资本和公司的一般需要。 Proceeds will also support working capital and general corporate needs. SEC宣布登记表于2025年9月29日生效。 The SEC declared the registration statement effective September 29, 2025.